Drug Trial Radar · NCT05016323
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
316
Actual
Start
Sep 9, 2021
Primary completion
Jun 9, 2024
Study completion Aug 15, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of HR19042 capsules compared to matching placebo for the treatment of primary IgA nephropathy, and explore the optimal dose for the treatment.
Conditions
- IgA Nephropathy
Interventions
HR19042 CapsulesDrug
HR19042 Capsules
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in urine protein creatinine ratio (UPCR)Time frame: 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NanFang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.